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Editorial
Jérôme Guéchot, Jérôme Boursier, Victor de Ledinghen, Thierry Poynard, Fabrice Carrat, 
Vincent Leroy, Grace Lai-Hung Wong, Mireen Friedrich-Rust, Mirella Fraquelli, Mario Plebani, 
Giada Sebastiani, Robert Myers, Paul Angulo, Sandrine Bertrais, Dominique Wendum, 
Ivan Bricault and Paul Calès, from the ARDENT group and/or AFEFa
Liver-FibroSTARD checklist and glossary: tools for 
standardized design and reporting of diagnostic 
accuracy studies of liver fibrosis tests
DOI 10.1515/cclm-2015-0241
Chronic liver diseases are highly prevalent and require an 
accurate evaluation of liver fibrosis to determine patient 
management. Many efforts have been made over this last 
decade to develop accurate non-invasive tools for liver 
fibrosis evaluation as alternative methods to liver biopsy. 
These non-invasive methods of liver fibrosis assessment 
including blood markers and liver stiffness measurement 
by elastography are increasingly well validated and con-
tribute to safer and more practical clinical care for patients 
[1, 2]. These efforts have led to a dramatic increase in the 
number of diagnostic accuracy studies of liver fibrosis 
tests and to a proliferation of reports whose quality is very 
heterogeneous.
The validation of the diagnostic test is a critical issue 
for their widespread use in clinical practice [3]. The results 
of diagnostic accuracy studies are the basis to inform how 
to interpret test results and to consider the likelihood that 
errors occur in clinical decision. Guidelines aim to help for 
reporting the researches more completely to ensure that 
the papers are more useful and are not misleading [4]. The 
Standards for Reporting of Diagnostic Accuracy Studies 
(STARD), simultaneously published in 2003 in 13 biomedi-
cal journals, including Clinical Chemistry and Laboratory 
Medicine [5] were developed aiming to “improve the accu-
racy and completeness of reporting of studies of diagnos-
tic accuracy, to allow readers to assess the potential for 
bias in the study (internal validity) and to evaluate its 
generalizability (external validity)”. The STARD checklist, 
comprising 25 items summarizing the important informa-
tion that has to be present in scientific reports, has been 
included in the instructions to authors of more than 200 
scientific journals. Over the years, the reporting of many 
individual STARD items improved however, the STARD 
authors agreed that these statements should be updated 
[6] and the original checklist was supplemented with guid-
ance pertinent to studies of specific disorders in human 
[7–9], veterinary medicine [10] or epidemiology [11].
For the diagnostic accuracy studies of non-invasive 
liver fibrosis tests, the STARD criteria represent an excel-
lent base to start off. However, these studies have particu-
lar features that are not taken into account by the current 
STARD statements. While fibrosis staging is of high clini-
cal significance in patients with chronic liver diseases, the 
difficulties due not only to the absence of an absolute gold 
standard (liver biopsy examination is a limited “gold” 
standard [12]), but also to the spectrum bias [13], and to 
the specificities for ordinal references such as pathologi-
cal staging [14] made essential to develop specific vali-
dated standards of study design and reporting.
A group of eight experts of different specialties (hepa-
tology, biology, radiology, pathology, and biostatistics) 
chosen by the board of the French Association for the 
Study of the Liver [Association Française pour l’Étude du 
Foie (AFEF)] evaluated STARD statements adequacy in 10 
diagnostic studies about non-invasive liver fibrosis tests, 
and considered than more than a half of the 25 STARD 
items were only partially adequate for this purpose [15]. 
Therefore, they attempted to establish a consensus for 
quality standards by adapting the STARD criteria to the 
requirements of liver fibrosis testing and then developed 
an extended version developed specifically for those 
studies. The process resulted in introducing two new items 
and 42 sub-items within the 25 STARD items [16]. A com-
prehensive glossary including explanations and examples 
for each item/sub-item was also drafted and approved by 
the panel of experts [17].
The Liver-FibroSTARD checklist and glossary were 
independently submitted to seven international experts 
in order to test and validate the new standard statements. 
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The independent evaluation showed at least very good 
inter-expert agreement for two thirds of the items/sub-
items [15]. After this second external evaluation, material 
was finally improved. The new Liver-FibroSTARD check-
list [16] and glossary [17] are freely available at the URLs 
mentioned in these references.
An accelerated development of improved markers 
has been recommended in order to integrate non-inva-
sive tests of liver fibrosis as endpoints into future clinical 
trial design of antifibrotic drug [18]. High-quality studies 
are required for validation of cut-offs to stage fibrosis 
according to the etiologies of chronic liver diseases [19]. 
As a supplement of the STARD statements, the Liver-
FibroSTARD checklist and its glossary are new tools spe-
cifically designed for the evaluation of diagnostic studies 
about non-invasive liver fibrosis tests. Liver-FibroSTARD 
statements should allow improving design and reporting 
in this field and could be the beginning of an iterative 
process by which reporting standards will be continu-
ously improved.
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